Annotation Detail

Information
Associated Genes
ABL1
Associated Variants
ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I)
Associated Disease
acute lymphoblastic leukemia
Source Database
CIViC Evidence
Description
Bone marrow mononuclear cells (BM MNCs) isolated from three acute lymphoblastic leukemia patients with the BCR-ABL1 T315I variant. Patients were pretreated with various chemotherapeutics and dasatinib. The patients' cells were sensitive to Ponatinib and Axitinib and insensitive to Nilotinib, Imatinib, and Dasatinib using drug sensitivity scoring detailed in a referenced paper. Additionally, in a proliferation assay, T315I variants were resistant to imatinib.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7778
Gene URL
https://civic.genome.wustl.edu/links/genes/4
Variant URL
https://civic.genome.wustl.edu/links/variants/2
Rating
3
Evidence Type
Predictive
Disease
Acute Lymphoblastic Leukemia
Evidence Direction
Supports
Drug
Imatinib,Dasatinib,Nilotinib
Evidence Level
D
Clinical Significance
Resistance
Pubmed
25686603
Drugs
Drug NameSensitivitySupported
DasatinibResitance or Non-Reponsetrue
ImatinibResitance or Non-Reponsetrue
NilotinibResitance or Non-Reponsetrue